drugset
drugset / Trial / NCT00135512

Study Of 323U66 SR In Major Depressive Disorder

NCT00135512 ↗

Phase 2 Completed 234 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study was designed to evaluate the efficacy and safety in major depressive disorder patients.

Timeline

Start
2004-12-01
Primary completion
2007-05-28
Completion
2007-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule — —

Indications

major depressive disorder